IL144957A0 - Granulate with high content of l-carnitine or an alkanoyl l-carnitine, particularly suitable for the production of tablets by direct compression - Google Patents

Granulate with high content of l-carnitine or an alkanoyl l-carnitine, particularly suitable for the production of tablets by direct compression

Info

Publication number
IL144957A0
IL144957A0 IL14495700A IL14495700A IL144957A0 IL 144957 A0 IL144957 A0 IL 144957A0 IL 14495700 A IL14495700 A IL 14495700A IL 14495700 A IL14495700 A IL 14495700A IL 144957 A0 IL144957 A0 IL 144957A0
Authority
IL
Israel
Prior art keywords
carnitine
granulate
direct compression
high content
tablets
Prior art date
Application number
IL14495700A
Other languages
English (en)
Original Assignee
Biosint S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosint S P A filed Critical Biosint S P A
Publication of IL144957A0 publication Critical patent/IL144957A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Confectionery (AREA)
IL14495700A 1999-03-26 2000-03-22 Granulate with high content of l-carnitine or an alkanoyl l-carnitine, particularly suitable for the production of tablets by direct compression IL144957A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999RM000189A IT1305308B1 (it) 1999-03-26 1999-03-26 Granulato ad alto contenuto di l-carnitina o alcanoil-l-carnitina,particolarmente adatto alla produzione di compresse per compressione
PCT/IT2000/000097 WO2000057873A2 (en) 1999-03-26 2000-03-22 Granulate with high content of l-carnitine or an alkanoyl l-carnitine

Publications (1)

Publication Number Publication Date
IL144957A0 true IL144957A0 (en) 2002-06-30

Family

ID=11406608

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14495700A IL144957A0 (en) 1999-03-26 2000-03-22 Granulate with high content of l-carnitine or an alkanoyl l-carnitine, particularly suitable for the production of tablets by direct compression
IL144957A IL144957A (en) 1999-03-26 2001-08-16 Granules with a high content of L-carnitine or L-carnitine alkanol, especially suitable for the production of tablets by direct compression

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL144957A IL144957A (en) 1999-03-26 2001-08-16 Granules with a high content of L-carnitine or L-carnitine alkanol, especially suitable for the production of tablets by direct compression

Country Status (20)

Country Link
US (1) US6485741B2 (de)
EP (1) EP1171111B1 (de)
JP (2) JP4637367B2 (de)
KR (1) KR100729848B1 (de)
CN (1) CN1158072C (de)
AT (1) ATE238784T1 (de)
AU (1) AU780413B2 (de)
CA (1) CA2363038C (de)
CZ (1) CZ301266B6 (de)
DE (1) DE60002454T2 (de)
DK (1) DK1171111T3 (de)
ES (1) ES2197867T3 (de)
HU (1) HU228588B1 (de)
IL (2) IL144957A0 (de)
IT (1) IT1305308B1 (de)
PL (1) PL207961B1 (de)
PT (1) PT1171111E (de)
SK (1) SK285565B6 (de)
TR (1) TR200102802T2 (de)
WO (1) WO2000057873A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1047889B (en) * 1999-09-03 2009-04-09 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Ultrafine l-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same
CN1686089B (zh) * 2005-05-08 2010-08-18 北京健健康康生物技术有限公司 一种可直接压片的木糖醇颗粒及其制备方法
CN101912045B (zh) * 2005-07-05 2013-07-31 隆萨股份公司 生产干肉碱粉末或颗粒的喷雾干燥法
MX342962B (es) * 2009-09-18 2016-06-07 Teva Pharmaceuticals Holdings Mexico S A De C V Composicion farmaceutica para bajar de peso y procedimiento para obtener la misma.
EP2335495A1 (de) 2009-12-11 2011-06-22 Lonza Ltd. Carnitin-Granulat und Verfahren zu dessen Herstellung
CN102349881B (zh) * 2011-10-26 2013-06-26 东北制药（沈阳）科技发展有限公司 一种左卡尼汀薄膜衣片及其制备方法
CN105695398A (zh) * 2016-04-25 2016-06-22 广西大学 含o-乙酰基-l-肉碱盐酸盐的水牛卵母细胞体外成熟液及培养方法
JP7366612B2 (ja) * 2019-07-09 2023-10-23 東和薬品株式会社 レボカルニチンを含有する錠剤
KR20230011999A (ko) 2020-05-15 2023-01-25 알파시그마 에스.피.에이. 메틸폴레이트를 포함하는 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2921852A1 (de) * 1979-05-29 1980-12-11 Fresenius Chem Pharm Ind Lipide senkendes mittel
IT1119853B (it) * 1979-09-21 1986-03-10 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente l-carnitina per il trattamento delle dislipidemie ed iperlipo proteinemie
JPS59222412A (ja) * 1983-06-01 1984-12-14 Earth Chem Corp Ltd 心臓疾患治療薬
DE3463261D1 (en) * 1983-12-28 1987-05-27 Sigma Tau Ind Farmaceuti Salts of l-carnitine and alkanoyl l-carnitines and process for preparing same
IT1181682B (it) * 1985-06-11 1987-09-30 Sigma Tau Ind Farmaceuti Impiego di alcanoil l-carnitine per il trattamento terapeutico del parkinsonismo idiopatico o indotto
IT1190370B (it) * 1985-06-19 1988-02-16 Zambon Spa Composizione farmaceutica solida per uso orale
JPH03120211A (ja) * 1989-10-04 1991-05-22 Earth Chem Corp Ltd 粒状カルニチン製剤
US5073376A (en) * 1989-12-22 1991-12-17 Lonza Ltd. Preparations containing l-carnitine
JPH0656659A (ja) * 1992-06-10 1994-03-01 Natl Sci Council 直接打錠できる薬学組成物及びその錠剤の製造法
EP0681839A3 (de) * 1994-05-12 1997-11-12 Hirohiko Kuratsune Acylcarnitin-enthaltende pharmazeutische Zusammensetzung
JPH0812569A (ja) * 1994-06-24 1996-01-16 Takeda Chem Ind Ltd 塩化カルニチン吸着固形物
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
JP3120211B2 (ja) 1996-05-14 2000-12-25 スガツネ工業株式会社 オーバーヘッドドア開閉用ダンパー
US5837292A (en) * 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
DE19629753A1 (de) * 1996-07-23 1998-01-29 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
IT1291126B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Composizioni solide atte alla somministrazione orale comprendenti sali non igroscopici della l-carnitina e delle alcanoil l-carnitine
IT1291133B1 (it) * 1997-04-07 1998-12-29 Sigma Tau Ind Farmaceuti Composizioni solide atte alla somministrazione orale comprendenti l-carnitina e alcanoil l-carnitine magnesio tartrato
IT1290600B1 (it) * 1997-04-30 1998-12-10 Sigma Tau Ind Farmaceuti Composizioni solide atte alla somministrazione orale comprendenti l-carnitina e alcanoil l-carnitine magnesio fumarato

Also Published As

Publication number Publication date
DK1171111T3 (da) 2003-08-25
DE60002454D1 (de) 2003-06-05
TR200102802T2 (tr) 2002-04-22
PT1171111E (pt) 2003-09-30
CN1158072C (zh) 2004-07-21
JP2002540153A (ja) 2002-11-26
AU780413B2 (en) 2005-03-17
HUP0200465A2 (en) 2002-06-29
US20020025984A1 (en) 2002-02-28
CA2363038C (en) 2008-10-14
JP2001097353A (ja) 2001-04-10
WO2000057873A3 (en) 2001-04-19
EP1171111B1 (de) 2003-05-02
ES2197867T3 (es) 2004-01-16
KR20010114227A (ko) 2001-12-31
JP4637367B2 (ja) 2011-02-23
PL207961B1 (pl) 2011-02-28
HU228588B1 (en) 2013-04-29
DE60002454T2 (de) 2004-03-18
ITRM990189A1 (it) 2000-09-26
PL350908A1 (en) 2003-02-10
ATE238784T1 (de) 2003-05-15
CZ301266B6 (cs) 2009-12-23
CN1345235A (zh) 2002-04-17
IL144957A (en) 2006-08-01
US6485741B2 (en) 2002-11-26
KR100729848B1 (ko) 2007-06-19
SK11592001A3 (sk) 2001-12-03
AU3834400A (en) 2000-10-16
CA2363038A1 (en) 2000-10-05
EP1171111A2 (de) 2002-01-16
IT1305308B1 (it) 2001-05-04
CZ20013078A3 (cs) 2002-02-13
WO2000057873A2 (en) 2000-10-05
SK285565B6 (sk) 2007-03-01

Similar Documents

Publication Publication Date Title
AU2003286994A1 (en) Modified release pharmaceutical composition
CA2091370A1 (en) Tablets, granulates and pellets with a high active substance content for highly concentrated, solid dosage forms
CA2199778A1 (en) Extended release formulation of venlafaxine
MY124695A (en) Novel composition and use.
NO841518L (no) Delbare tabletter med forsinket frigjoering av virkestoff, og fremgangsmaate for fremstilling derav
ZA200000169B (en) Process for the preparation of pellets with a content of up to 90 wt.% of a pharmaceutical active ingredient.
IL150528A0 (en) Ibuprofen containing active agent preparation
AU2793989A (en) Method for preparing a solid sustained release form of a functionally active composition and the dosage form so obtained
IL144957A0 (en) Granulate with high content of l-carnitine or an alkanoyl l-carnitine, particularly suitable for the production of tablets by direct compression
AU590370B2 (en) Improvements in or relating to pharmaceutical products
EA199900102A1 (ru) Таблетка малеата тримебутина, покрытая оболочкой
AU4519399A (en) Anti-inflammatory pharmaceutical formulations
AP1901A (en) Pharmaceutical composition for modified release insulin sensitiser.
HU9403160D0 (en) More easily biologically absorbed tablet containing dichloromethylene diphosphonic acid as the active agent
GB2295966B (en) Direct compression tablets
WO1999018941A3 (en) Ih-MODULATORS
AU3970793A (en) Methods of manufacturing high dosage glutathione, the tablets and capsules produced thereby
BG102692A (en) Pharmaceutical forms with delayed release, containing misolastin
ES2169980A1 (es) Microcapsulas para la liberacion prolongada de farmacos.
GB9415048D0 (en) Tablet
WO2002041897A3 (fr) Compositions pharmaceutiques a action antidiabetique constitues de l'association d'un biguanide et d'un sulfonamide
CA2473718A1 (en) Immediate-release pharmaceutical dosage form comprising polymorphous tibolone
SI1171111T1 (en) Granulate with high content of l-carnitine or an alkanoyl l-carnitine, particularly suitable for the production of tablets by direct compression

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed